Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer to present Campath and Leukine data

Bayer to present Campath and Leukine data

8th December 2008

Bayer has said it will present data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) at an annual meeting.

Clinical investigators from oncology and hematology research centres will present data through oral and poster presentations – reporting important findings in leukemia-related disorders.

This includes prognostic indicators for chronic lymphocytic leukemia and its side effects, such as chemotherapy-induced neutropenia.

Vice-president of medical affairs and oncology at Bayer Healthcare, Pam Cyrus, said she was “pleased” to see the continuing development of Leukine and Campath.

She went on to say: “These studies further demonstrate Bayer’s ongoing commitment to supporting research to benefit the lives of people living with cancer.”

Campath is a single agent for the treatment of B-cell chronic lymphocytic leukemia, while Leukine is used following the induction of chemotherapy in patients 55 years and older with acute myelogenous leukemia – in order to shorten the time neutrophil recovery takes, along with reducing the incidence of severe and life-threatening infections.

In other news, Bayer Healthcare and Protagen have said they have signed a cooperation contract, in order evaluate UNIarray technology.

Used for discovery of novel biomarkers in atrial fibrillation, Bayer Healthcare is currently intending to use the method to investigate the cardiac arrhythmia after heart surgery.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.